SOPHIA ANTIPOLIS, France – April 28, 2025 │ The therapeutic RNA landscape continues to evolve with a robust pace of innovation. The latest Q1 2025 edition of our Therapeutic mRNA patent monitor highlights significant developments in intellectual property activities, shedding light on key contributors and trends in this dynamic field. BioNTech, Sanofi, Penn, and Moderna[…]
SOPHIA ANTIPOLIS, France – February 04, 2025 │ KnowMade actively tracks therapeutic mRNA innovations as part of its Therapeutic mRNA patent monitoring services. What’s new today? CHMP Recommends Approval of KOSTAIVE® (ARCT-154) EMA opinion The European Medicines Agency (EMA)’s Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion recommending the approval[…]
SOPHIA ANTIPOLIS, France – January 30, 2025 │ The last quarterly report for the 2024 Therapeutic mRNA patent monitor is now available! As we leave behind another year, we look back on the mRNA therapeutic patenting activity! The year 2024 marked another dynamic period for technological innovation in mRNA therapeutic area, the race for intellectual[…]
SOPHIA ANTIPOLIS, France – January 20, 2025 │ The therapeutic RNA landscape continues to evolve with a robust pace of innovation. The latest Q4 2024 edition of our Therapeutic mRNA patent monitor highlights significant developments in intellectual property activities, shedding light on key contributors and trends in this dynamic field. Key Highlights from Q4 2024[…]